A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
October 2018 IPO Filings and Proceeds, Updated 10/31/2018
Know of an IPO since Oct. 1, 2018 that we missed? Email us at news@biospace.com.
| Date | Company Name | Amount (USD) | Company HQ | Research Focus |
|---|---|---|---|---|
| 10/31/18 | Orchard Therapeutics | $200M Priced | London, UK | Gene therapy for primary immune deficiencies & inherited metabolic disorders |
| 10/31/18 | Axonics Modulation Technologies | $120M Priced | Irvine, CA | Medical devices with innovative neuromodulation platform for urinary and fecal dysfunction |
| 10/31/18 | Twist Bioscience | $70M Priced | San Francisco, CA | Silicon-based DNA synthesis platform |
| 10/31/18 | Guardion Health Sciences, Inc. | $10M Filed | San Diego, CA | Targeted ocular nutrition and diagnostic technology for eye diseases |
| 10/26/18 | Gamida Cell Ltd. | $50M Priced | Jerusalem, Israel | Cell therapies for cancer and rare genetic diseases |
| 10/22/18 | Glucose Biosensor Systems Holdings, Inc. | $25M Filed | New York, NY | Commercializing novel “smart” biosensor salivary glucose monitoring system |
| 10/19/18 | Centrexion | $86.3M Filed | Baltimore, MD | Novel non-opioid therapies for severe chronic pain |
| 10/19/18 | Vapotherm Inc. | $58M Filed | Exeter, NH | Hi-VNI® technology company for respiratory distress |
| 10/18/18 | LogicBio Therapeutics | $80.5M Priced | Cambridge, MA | Genome editing in rare diseases for pediatric patients |
| 10/17/18 | PhaseBio Pharmaceuticals | $46M Priced | Malvern, PA | Novel therapies to treat orphan diseases, especially cardiopulmonary |
| 10/17/18 | Osmotica Pharmaceutical | $46.6M Priced | Bridgewater, NJ | Generic drugs for neurology and women’s health |
| 10/16/18 | SI-BONE, Inc. | $108M Priced | Santa Clara, CA | Medical device company treating SI joint pain with the iFuse Implant System® |
| 10/12/18 | Equillium, Inc. | $65.4M Priced | La Jolla, CA | Monoclonal antibodies to treat severe immuno-inflammatory diseases |
| 10/10/18 | Allogene Therapeutics | $372.6M Priced | South San Francisco, CA | Allogenic CAR-T therapies for blood cancer and solid tumors |
| 10/10/18 | Hoth Therapeutics | $13M Filed | New York City, NY | Proprietary therapeutics for atopic dermatitis |
| 10/5/18 | Axonics Modulation Technologies | $86.25M Filed | Irvine, CA | Medical devices with innovative neuromodulation platform for urinary and fecal dysfunction |
| 10/4/18 | Orchard Therapeutics | $172.5M Filed | London, UK | Gene therapy for primary immune deficiencies & inherited metabolic disorders |
| 10/3/18 | Guardant Health | $237.5M Priced | Redwood City, CA | Blood tests for early and recurrent cancer detection and treatment selection |
| 10/3/18 | Kodiak Sciences Inc. | $90M Priced | Palo Alto, CA | Antibody bipolymer conjugates in retinal disease |
| 10/2/18 | Twist Bioscience | $86.25M Filed | San Francisco, CA | Silicon-based DNA synthesis platform |
